Implicit Bioscience

This early-stage study tests a monoclonal antibody called atibuclimab (IC14) in 10 adults who had a severe heart attack (STEMI) and received a stent. The drug is given by IV to see if it can prevent further heart muscle damage and reduce inflammation. Participants are compared to…

This study aimed to test a drug called IC14 in people with acute respiratory distress syndrome (ARDS), a severe lung condition. Participants would have received IC14 or a placebo for 4 days and been followed for 28 days. The trial was withdrawn before enrolling anyone, so no resu…

This study aimed to test a drug called IC14 in adults with dengue fever to see if it was safe and could help reduce symptoms and viral levels. It was designed for people in areas where dengue is common who had a fever for less than 48 hours. However, the study was withdrawn befor…

This study aimed to test an experimental drug called IC14 in 50 people with rapidly progressing ALS. Participants would have received either the drug or a placebo intravenously twice a week for 12 weeks. The goal was to measure changes in disease markers and track safety. However…

This early-stage trial tests a drug called atibuclimab (IC14) in 10 adults hospitalized with acute decompensated heart failure. The main goals are to check if the drug is safe and to measure its levels in the blood. Researchers will also look at how it affects heart failure marke…

This study was designed for people with rapidly progressing ALS. It aimed to see if the drug IC14 could change brain inflammation measured by special PET scans. The study was withdrawn before any participants were enrolled, so no results are available.